RSV Infection With Inflammatory Bowel Disease Ups Risk for Hospitalization
By Lori Solomon HealthDay Reporter
WEDNESDAY, Aug. 28, 2024 -- Adult patients with inflammatory bowel disease (IBD) and respiratory syncytial virus (RSV) infection have an increased risk for hospitalization, according to a study published online in the August issue of The American Journal of Gastroenterology.
Ryan A. Smith, M.D., from University of Wisconsin in Madison, and colleagues sought to determine whether patients with IBD have an increased risk for a serious infection due to RSV. The analysis included data from 794 patients with IBD and 93,074 propensity-matched non-IBD patients with RSV.
The researchers found that the IBD-RSV cohort had an increased risk for hospitalization (adjusted odds ratio [aOR], 1.30; 95 percent confidence interval [CI], 1.06 to 1.59). There was no difference between the groups in the risk (aOR, 0.83; 95 percent CI, 0.58 to 1.19) for a composite outcome of hospitalization-related complications. There was an association between recent systemic corticosteroid use (less than three months) and an increased risk for hospitalization (aOR, 1.86; 95 percent CI, 1.30 to 2.59) in the IBD-RSV cohort.
"Adult patients with IBD and RSV infection are at an increased risk of hospitalization and may benefit from the new RSV vaccine recommended for adults aged 60 years and older," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2024
Read this next
RSV Vaccines, Nirsevimab Tied to Reduced RSV-Linked Hospitalization
TUESDAY, May 13, 2025 -- Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated hospitalization rates among...
Nirsevimab Effective for Reducing Burden of RSV in Infants
THURSDAY, May 8, 2025 -- Nirsevimab is effective for reducing the burden of respiratory syncytial virus (RSV) in infants in real-world settings, according to a study published...
Spatiotemporal Mapping IDs Four Stages of Inflammatory Bowel Disease Evolution
TUESDAY, May 6, 2025 -- Machine learning has enabled spatiotemporal mapping of the four stages of the evolution of inflammatory bowel disease (IBD), according to a study published...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.